High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT

被引:291
作者
Rezvani, Katayoun
Mielke, Stephan
Ahmadzadeh, Mojgan
Kilical, Yasemin
Savani, Bipin N.
Zeilah, Josette
Keyvanfar, Keyvan
Montero, Aldemar
Hensel, Nancy
Kurlander, Roger
Barrett, A. John
机构
[1] NHLBI, Stem Cell Allogenec Transplant Sect, Hematol Branch, DIR,NIH, Bethesda, MD 20892 USA
[2] NCI, Dept Surg, Bethesda, MD 20892 USA
[3] NIH, Dept Lab Med, Bethesda, MD 20892 USA
关键词
D O I
10.1182/blood-2006-02-003996
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Regulatory T cells (TregS) that constitutively express FOXP3 are instrumental to the maintenance of tolerance and may suppress graft-versus-host disease (GVHD) in humans. To determine whether regulatory T cells in allogeneic stem cell transplants (SCTS) ameliorate GVHD after transplantation, we quantitated the coexpression of FOXP3 on CD4(+) T cells in 32 donor SCTs infused into HLA-matched siblings and examined GVHD incidence in respective recipients. High CD4(+)FOXP3(+) T-cell count in the donor was associated with a reduced risk of GVHD. We monitored T(reg)s during immune reconstitution in 21 patients with leukemia undergoing a T-cell-depleted allogeneic SCT. Early after SCT, there was a significant expansion in the CD4(+)FOXP3(+) T-cell compartment. A low CD4(+)FOXP3(+) T-cell count early after SCT, (day 30) was associated with an increased risk of GVHD, and the ratio of CD4(+)FOXP3(+) T cells to CD4(+)CD25(+)FOXP3(-) T cells was significantly reduced in patients with GVHD, suggesting diminished control of effector T cells. Our findings suggest that graft T-reg content may predict for risk of GVHD after SCT Determining the T-reg levels in the donor and manipulating T-regs early after transplantation may provide a new approach to controlling GVHD.
引用
收藏
页码:1291 / 1297
页数:7
相关论文
共 47 条
[1]   IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients [J].
Ahmadzadeh, M ;
Rosenberg, ST .
BLOOD, 2006, 107 (06) :2409-2414
[2]   Regulatory T cells under scrutiny [J].
Bach, JF .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (03) :189-198
[3]   CD4+CD25high regulatory cells in human peripheral blood [J].
Baecher-Allan, C ;
Brown, JA ;
Freeman, GJ ;
Hafler, DA .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1245-1253
[4]   Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions [J].
Blazar, BR ;
Lees, CJ ;
Martin, PJ ;
Noelle, RJ ;
Kwon, B ;
Murphy, W ;
Taylor, PA .
JOURNAL OF IMMUNOLOGY, 2000, 165 (09) :4901-4909
[5]  
BLAZAR BR, 1994, BLOOD, V83, P3815
[6]   Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells [J].
Clark, FJ ;
Gregg, R ;
Piper, K ;
Dunnion, D ;
Freeman, L ;
Griffiths, M ;
Begum, G ;
Mahendra, P ;
Craddock, C ;
Moss, P ;
Chakraverty, R .
BLOOD, 2004, 103 (06) :2410-2416
[7]   Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells [J].
Coenen, JJA ;
Koenen, HJPM ;
van Rijssen, E ;
Hilbrands, LB ;
Joosten, I .
BLOOD, 2006, 107 (03) :1018-1023
[8]   CD4+CD25+ immunoregulatory T cells:: New therapeutics for graft-versus-host disease [J].
Cohen, JL ;
Trenado, A ;
Vasey, D ;
Klatzmann, D ;
Salomon, BL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (03) :401-406
[9]   Cutting edge:: Self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells [J].
Cozzo, C ;
Larkin, J ;
Caton, AJ .
JOURNAL OF IMMUNOLOGY, 2003, 171 (11) :5678-5682
[10]  
Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514